1. Home
  2. News
  3. Imugene Ltd
  4. New Dose Escalation in Phase I Clinical Trial of CHECKvacc
More Imugene Ltd news
Imugene LtdASX: IMU

New Dose Escalation in Phase I Clinical Trial of CHECKvacc

Jul 6, 2023 at 11:17 PM EDT · Issued by Imugene Ltd

Filed with ASX · Jul 6, 2023 at 11:17 PM EDT · 4 pages · English

On 6ix: 6ix.com/news/new-dose-escalation-in-phase-i-clinical-trial-of-checkvacc

Imugene Ltd on 6ix

Story so far

  • Imugene Images and Follows CHECKVacc in TNBC PatientsApr 20, 2023
  • CHECKVacc Data Presented at the 2022 SABC SymposiumDec 9, 2022
  • Dose escalates In Phase I Clinical Trial of New Oncolytic ViNov 11, 2022

Earlier from Imugene

  • HER-Vaxx induced antibodies correlated with tumour reductionJun 29, 2023
  • Imugene PD1-Vaxx patent extended to 2040Jun 28, 2023
  • Imugene Advances VAXINIA MAST Trial to Next IV CohortsJun 8, 2023
  • Imugene doses first combination patient in PD1-Vaxx trialMay 31, 2023
  • Imugene secures IND approval for first-in-class onCARlytics trialMay 19, 2023

Later from Imugene

  • Imugene Oncolytic Virotherapy CF33 Patent Allowed in the USJul 19, 2023
  • Imugene and RenovoRx CF33 Virotherapy Delivery CollaborationJul 20, 2023
  • Imugene HER-Vaxx and CHECKVacc to be Featured at ESMOJul 24, 2023
  • Imugene CF33 Oncolytic Virus Study to be Showcased at SITCAug 2, 2023
  • Imugene VAXINIA Trial clears Cohort 3 of IT MonotherapyAug 13, 2023
All Imugene news releases↗

Follow Imugene into a list and get an email when it puts out news.

Follow Imugene
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer